Drug Profile

Azilsartan mepixetil - Wuhan Createrna Science and Technology

Alternative Names: QR-01019

Latest Information Update: 10 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wuhan Createrna Science and Technology
Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Esters; Ethers; Oxadiazoles; Pyrazines; Small molecules
Mechanism of Action Angiotensin type 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 May 2023 US FDA approves clinical trial application for Azilsartan mepixetil in Essential hypertension (before May 2023)
26 May 2023 Wuhan Createrna Science and Technology plans a clinical trial for Essential hypertension in the US
17 Dec 2021 Phase-II clinical trials in Hypertension in China (PO), before December 2021 (Wuhan Createrna Science and Technology pipeline, December 2021).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com